Sharemaestro company-news research for Artivion Inc (AORT), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NYSE
United States
Provisional evidence
Company news sentiment
Latest AORT news and sentiment
Artivion Inc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
10 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone47/100
→
Published 30-day score50/100
Latest source headline
Artivion Inc. (AORT) Q2 2026 Earnings: Reported Loss of $0.28 Per Share Overshadows Consensus Estimate
https://www.dars.gov.et/ · 04 Oct 2026 12:46
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
10 current stories are mapped specifically to AORT.
What limits the score
Only 2 publishers currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.034.
Confidence is 18/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
18/100
Confidencethin evidence
100%/100
Company news10 company stories
91/100
Story agreement9/100 difference
News history
Daily score and story count over 30 days
15 Sep30 Sep14 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence1
0.034 after freshness weightingSource breadth40
2 independent publishersCompany relevance100
share tied directly to this companyFreshness9
recency-weighted evidenceAgreement91
how closely stories agreePublisher mix20
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202650USD 21.26-4.7%
02 Oct 202651USD 22.31-1.4%
25 Sep 202650USD 22.63-3.1%
18 Sep 202649USD 23.35-6.9%
11 Sep 202649USD 25.08-1.9%
04 Sep 202651USD 25.57-4.5%
28 Aug 202649USD 26.77-4.7%
21 Aug 202654USD 28.08-3.6%
Provisional evidence
News subjects
What is shaping the score
Earnings453 stories · 30%
Market update503 stories · 30%
Balance sheet502 stories · 20%
Analyst action721 stories · 10%
Deals and strategy471 stories · 10%
Source mix
Where the evidence comes from
TradingView505 stories · 50%
Moomoo721 stories · 10%
https://www.dars.gov.et/431 stories · 10%
Insider Monkey471 stories · 10%
Simply Wall Street521 stories · 10%
Yahoo! Finance Canada501 stories · 10%
Recurring subjects
Subjects appearing most often
Financial Markets8Earnings7Life Sciences6Finance4Medical Devices1Fda Approval1Acquisition1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
26 Jun50 neutral14 Oct 23:48
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 14 Oct 23:48 | 50 | +0 | 18/100 (-9) | 10 (-5) | Provisional |
| 04 Oct 23:59 | 50 | -1 | 27/100 (+6) | 15 (-1) | Provisional |
| 30 Sep 23:59 | 51 | -1 | 21/100 (-2) | 16 (+3) | Provisional |
| 29 Sep 23:59 | 52 | +0 | 23/100 (-5) | 13 (0) | Provisional |
| 27 Sep 23:59 | 52 | +3 | 28/100 (+9) | 13 (0) | Provisional |
| 24 Sep 23:59 | 49 | +0 | 19/100 (-4) | 13 (-6) | Provisional |
| 18 Sep 23:59 | 49 | +0 | 23/100 (-3) | 19 (-6) | Provisional |
| 16 Sep 23:59 | 49 | +1 | 26/100 (-5) | 25 (-3) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 10 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Earnings1 story
88.5%0.0%
Analyst action1 story
0.0%11.5%
Each side uses the same scale: 0–88.5% of the retained directional evidence.
Where the influence comes from
88.5%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
43/100 tone
88.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 04 Oct 2026 12:46
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 39/100
- 30-day weight
- 88.5% of directional evidence · 10.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Diluted shares outstanding of Artivion, Inc. – HAN:CYL
This article provides financial information for Artivion, Inc. (HAN:CYL), specifically focusing on its diluted shares outstanding. The content is primarily a data placeholder from TradingView, indicating that specific value and change data for diluted shares outstanding would be displayed…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides financial information for Artivion, Inc. (HAN:CYL), specifically focusing on its diluted shares outstanding. The content is primarily a data placeholder from TradingView, indicating that specific value and change data for diluted shares outstanding would be displayed for various periods.
- Published
- 30 Sep 2026 12:58
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial Markets
—Unscored
Market updateNot used in direction
Total equity of Artivion, Inc. – HAN:CYL
The article focuses on the total equity information for Artivion, Inc. (CYL) traded on the Hannover Stock Exchange. It indicates that the market was closed with no trades at the time of the report. The content also briefly lists the various data providers and copyright information relevan…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
The article focuses on the total equity information for Artivion, Inc. (CYL) traded on the Hannover Stock Exchange. It indicates that the market was closed with no trades at the time of the report. The content also briefly lists the various data providers and copyright information relevant to the financial data presented.
- Published
- 30 Sep 2026 08:24
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceFinancial Markets
—Unscored
Balance sheetNot used in direction
Artivion, Inc. Statistics – HAN:CYL
This page provides financial statistics for Artivion, Inc. (CYL) traded on the Hannover Stock Exchange. It offers an overview of key financial ratios and metrics, including valuation, profitability, liquidity, solvency, and per-share metrics, with data available annually and quarterly fro…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This page provides financial statistics for Artivion, Inc. (CYL) traded on the Hannover Stock Exchange. It offers an overview of key financial ratios and metrics, including valuation, profitability, liquidity, solvency, and per-share metrics, with data available annually and quarterly from 2006 to 2025.
- Published
- 30 Sep 2026 04:57
- News subject
- Balance sheet
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
—Unscored
Balance sheetNot used in direction
Artivion, Inc. Cash Flow – HAN:CYL
This article provides a financial overview of Artivion, Inc. (CYL) focusing on its cash flow activities. It highlights the free cash flow for Q2 2026 as -10.52M EUR, with 2025 figures for free cash flow at 714.34K EUR and operating cash flow at 33.95M EUR. The content is primarily a data …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides a financial overview of Artivion, Inc. (CYL) focusing on its cash flow activities. It highlights the free cash flow for Q2 2026 as -10.52M EUR, with 2025 figures for free cash flow at 714.34K EUR and operating cash flow at 33.95M EUR. The content is primarily a data presentation, indicating the company's financial performance in terms of operating, investing, and financing cash flows.
- Published
- 29 Sep 2026 17:04
- News subject
- Balance sheet
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
—Unscored
EarningsNot used in direction
Artivion, Inc. Revenue Breakdown – NYSE:AORT
Artivion, Inc. (NYSE: AORT) reported a total revenue of $441.33 million USD last year. The Medical Devices segment was the top performer, contributing $345.82 million USD, an increase from $290.23 million USD the prior year. Geographically, the United States was the largest revenue genera…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Artivion, Inc. (NYSE: AORT) reported a total revenue of $441.33 million USD last year. The Medical Devices segment was the top performer, contributing $345.82 million USD, an increase from $290.23 million USD the prior year. Geographically, the United States was the largest revenue generator, accounting for $214.07 million USD.
- Published
- 27 Sep 2026 16:54
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsLife Sciences
72/100 tone
CCORF has reiterated its Buy rating for Artivion (AORT.US) and maintained a target price of $39. This suggests continued confidence in the company's performance and future outlook from the firm.
11.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
CCORF has reiterated its Buy rating for Artivion (AORT.US) and maintained a target price of $39. This suggests continued confidence in the company's performance and future outlook from the firm.
- Published
- 27 Sep 2026 07:54
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 48/100
- 30-day weight
- 11.5% of directional evidence · 17.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceFinancial Markets
—Unscored
Market updateNot used in direction
Artivion, Inc. (AORT) Stock Price, News, Quote & History
Artivion, Inc. (AORT) stock showed a slight increase after hours, following a dip at market close on September 25th. The company, which specializes in medical devices and implantable human tissues, has seen significant price fluctuations over various periods. Analyst ratings indicate a st…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Artivion, Inc. (AORT) stock showed a slight increase after hours, following a dip at market close on September 25th. The company, which specializes in medical devices and implantable human tissues, has seen significant price fluctuations over various periods. Analyst ratings indicate a strong buy consensus with a target price of $42.15.
- Published
- 24 Sep 2026 03:19
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
EarningsNot used in direction
AMDS Approval Could Be A Big Test For Artivion Stock (AORT)
Artivion (AORT) recently reported 11% Q2 2026 revenue growth but a net loss of US$13.5 million, despite securing FDA approval for its AMDS Hybrid Prosthesis and completing the Endospan acquisition. The company now boasts a complete aortic arch portfolio, but full-year revenue guidance rei…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Artivion (AORT) recently reported 11% Q2 2026 revenue growth but a net loss of US$13.5 million, despite securing FDA approval for its AMDS Hybrid Prosthesis and completing the Endospan acquisition. The company now boasts a complete aortic arch portfolio, but full-year revenue guidance reiteration highlights ongoing cost and profitability challenges. The investment narrative hinges on whether new products like AMDS can drive profitability and physician adoption without further margin erosion.
- Published
- 19 Sep 2026 04:27
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 25.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Deals and strategyNot used in direction
Artivion’s (AORT) Growth Story Hides A Widening Bottom-Line Problem
Artivion Inc. (AORT) reported strong Q2 2026 revenue growth of 11% and completed its aortic arch portfolio, yet simultaneously posted a net loss of $13.5 million, a significant reversal from the previous year's profit. The company's acquisitions and FDA approvals, while bolstering its pro…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Artivion Inc. (AORT) reported strong Q2 2026 revenue growth of 11% and completed its aortic arch portfolio, yet simultaneously posted a net loss of $13.5 million, a significant reversal from the previous year's profit. The company's acquisitions and FDA approvals, while bolstering its product lineup, are currently impacting profitability, leading to a reiterated rather than raised full-year guidance. This divergence between revenue growth and widening losses is creating uncertainty for investors, with a notable pullback in hedge fund holdings.
- Published
- 16 Sep 2026 02:49
- News subject
- Deals and strategy
- Why this score
- Deteriorating financial comparison, Operating growth
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.9d old
- Text assessed
- Stored article
- Duplicates
- 4 consolidated
AcquisitionEarningsFda ApprovalFinancial MarketsLife SciencesMedical Devices
Earlier company news
AORT news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 101 older AORT headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to AORT, but the headline and available text are not mainly about Artivion Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of AORT sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.